68Ga标记配体前列腺特异性膜抗原11 PET/CT在前列腺癌中的综合安全性评估:两项前瞻性多中心试验结果
两项前瞻性多中心试验共纳入88例新诊断或复发前列腺癌患者,评估68Ga-PSMA-11 PET/CT的临床安全性。结果显示无临床不良事件报告,血压和心率变化轻微,无患者需医疗干预,68Ga-PSMA-11 PET/CT耐受性良好。
要点
- 88例前列腺癌患者参与两项前瞻性试验,68Ga-PSMA-11给药剂量为2 MBq/kg体重。
- 未报告临床不良事件,收缩压和心率随时间显著下降,舒张压显著升高。
- 无患者出现低血压或需心血管干预,68Ga-PSMA-11 PET/CT耐受性良好。
核心结论
- 68Ga-PSMA-11 PET/CT耐受性很好,作者认为68Ga-PSMA-11用于人体是安全的。
研究设计与样本
- 两项前瞻性试验共纳入88例新诊断或复发前列腺癌患者,安全性报告方式相同。
- 68Ga-PSMA-11给药剂量为2 MBq/kg体重(平均9.2 μg,9.7 nmol)。
- 在注射前、注射后即刻、注射后1、10、60分钟及PET/CT扫描后测量血压和心率并记录不良事件。
主要发现
- 未报告临床不良事件。
- 收缩压(P < 0.001)和心率(P < 0.001)随时间显著下降,舒张压显著升高(P < 0.001)。
- 去除最后一次仰卧位观察后,收缩压和舒张压无时间依赖性变化,但心率显著变化仍存在。
- 整个观察期平均变化轻微:收缩压-6至5 mm Hg,舒张压-2至3 mm Hg,心率下降5次/分。
- 55例基线有高血压,其中15例CTCAE等级增加1级,2例增加2级;观察到大量无症状(1级)心动过缓,主要见于原有心动过缓患者;1例出现短暂1级心动过速。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to evaluate the clinical safety profile of the Ga-PSMA-11 ligand for PET/CT imaging in prospective clinical trials. METHODS: Eighty-eight patients with newly diagnosed or recurrent prostate cancer participated in 2 prospective trials. Safety reporting was identical in the 2 trials. The Ga-PSMA-11 ligand was administered as 2 MBq/kg body weight (mean, 9.2 μg, 9.7 nmol). The reporting of clinical adverse events (AEs) and the measurement of blood pressure (BP) and heart rate (HR) were performed prior to injection (baseline); immediately after injection of Ga-PSMA-11 (postinjection); at 1, 10, and 60 minutes after injection; and after acquisition of the PET/CT scan (postscan). All hemodynamic assessments were performed in the supine position, except for the postscan measurement (sitting). The patients were interviewed regarding any AEs at baseline, postinjection, or postscan. In addition, the patients were instructed to report any AEs during the investigation and to contact the investigator if AEs occurred during the rest of the day. Adverse events were classified as mild, moderate, or severe by the patients and categorized by the investigator using the CTCAE (Common Terminology Criteria for Adverse Events) version 4.0. RESULTS: There were no reported clinical AEs. There were significant decreases in systolic BP (P < 0.001) and HR (P < 0.001) over time. In comparison, the diastolic BP increased significantly (P < 0.001). After removal of the last observation (supine position), there was no time-dependent change in systolic or diastolic BP, but the significant change in HR remained. The mean changes over the entire observation period were minimal (systolic BP, -6 to 5 mm Hg; diastolic BP, -2 to 3 mm Hg; HR, decrease of 5 beats/min). No patients developed hypotension. Fifty-five patients presented with hypertension at baseline, which increased by 1 CTCAE grade in 15 patients and by 2 grades in 2 patients. A large number of cases of asymptomatic (grade 1) bradycardia were observed, primarily in patients with preexisting bradycardia. One patient developed transient grade 1 tachycardia. No patients required medical intervention for cardiovascular perturbations. CONCLUSIONS: Ga-PSMA-11 PET/CT was very well tolerated. We consider Ga-PSMA-11 to be safe for human application.
引用
- Nielsen JB, Zacho HD, Haberkorn U, et al. A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer: The Results of 2 Prospective, Multicenter Trials. Clin Nucl Med. 2017. PMID: 28481791. doi:10.1097/RLU.0000000000001681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。